The phase 1b first-MIND trial (NCT04134936) investigated the efficacy of the combination of tafasitamab +/− lenalidomide in combination with R-CHOP in patients with de novo DLBCL, showing a potential benefit of adding lenalidomide to R-CHOP and tafasitamab [9]. The gene discussed is DDIT3; the disease is diffuse large B-cell lymphoma.